NCT02818868 (ALVO) is a clinical trial of apixisaban in Ischemic Stroke, sponsored by Hyogo Medical University.

Who is sponsoring NCT02818868?

NCT02818868 is sponsored by Hyogo Medical University.

What drugs are being tested in NCT02818868?

Interventions in NCT02818868: apixisaban.

What condition does NCT02818868 study?

NCT02818868 studies Ischemic Stroke.

Is NCT02818868 still recruiting?

NCT02818868 is currently completed. Last updated 20 December 2021.

Last reviewed 2021-12-20 · How we verify

NCT02818868: ALVO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

Completed Last updated 20 December 2021

What this trial tests

trial testing apixisaban in Ischemic Stroke in 700 participants. Completed in 1 February 2018.

Timeline

1 July 2016

Primary endpoint
1 February 2018

1 February 2018

Quick facts

Lead sponsor	Hyogo Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	700
Start date	1 July 2016
Primary completion	1 February 2018
Estimated completion	1 February 2018
Sites	1 location across Japan

Drugs / interventions tested

apixisaban — full drug profile →

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Hyogo Medical University

Who can join

20 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Death
Time frame: 90 days after disease onset
Ischemic events
Time frame: 90 days after disease onset
Bleeding events
Time frame: 90 days after disease onset

Sponsor's own description

The aim of this study is to investigate the clinical events of the patients with acute cerebral large vessel occlusion or stenosis and atrial fibrillation, treated by apixaban within 14 days after onset. This is the observational study that patients will be made the registration at the timing of both retrospective period and prospective period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety of Early Administration of Apixaban on Clinical Outcomes in Patients with Acute Large Vessel Occlusion.
Yoshimura S, Uchida K, Sakai N, Imamura H, et al · · 2021 · cited 6× · PMID 32766953 · DOI 10.1007/s12975-020-00839-4

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Hyogo Medical University trials

Trials by the same sponsor.

NCT07347665 — Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle C · NA · recruiting
NCT06318286 — Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma · Phase 2 · recruiting
NCT03702413 — Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic Core · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02818868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hyogo Medical University
Last refreshed: 20 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02818868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing